• 1
    Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998; 91: 3995-4019.
  • 2
    Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010; 115: 206-214.
  • 3
    Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006; 43: 126-133.
  • 4
    Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762). Blood. 1992; 80: 2983-2990.
  • 5
    Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000; 36: 263-273.
  • 6
    Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002; 99: 1536-1543.
  • 7
    Wetzler M, Dodge RK, Mrozek K, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: a study of the Cancer and Leukemia Group B. Br J Hematol. 2004; 124: 275-288.
  • 8
    Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973; 243: 290-293.
  • 9
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247: 824-830.
  • 10
    Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in bcr/abl transgenic mice. Nature. 1990; 344: 251-253.
  • 11
    Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 1995; 86: 4603-4611.
  • 12
    Rieder H, Ludwig WD, Gassmann W, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Br J Hematol. 1996; 95: 678-691.
  • 13
    Heerema NA, Harbott J, Galimberti S, et al Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004; 18: 693-702.
  • 14
    Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol. 2009; 132: 940-949.
  • 15
    Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia. 2002; 16: 1233-1258.
  • 16
    Primo D, Tabernero MD, Perez JJ, et al. Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia. 2005; 19: 713-720.
  • 17
    Tabernero MD, Bortoluci AM, Alaejos I, et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. Leukemia. 2001; 15: 406-414.
  • 18
    Udomsakdi-Auewarakul C, Promsuwicha O, Tocharoentanaphol C, Munhketvit C, Pattanapanyasat K, Issaragrisil S. Immunophenotypes and outcome of Philadelphia chromosome-positive and -negative Thai adult acute lymphoblastic leukemia. Int J Hematol. 2003; 78: 337-343.
  • 19
    Paietta E, Racevskis J, Neuberg D, Rowe JM, Goldstone AH, Wiernik PH. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia. 1997; 11: 1887-1890.
  • 20
    Attarbaschi A, Mann G, Konig M, et al. Mixed lineage leukemia-rearranged childhood pro-B and CD10 negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res. 2006; 12: 2988-2994.
  • 21
    Abdelhaleem M. Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. Exp Mol Pathol. 2007; 83: 138-141.
  • 22
    Borowitz MJ. Precursor lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL et al, eds. World Health Organization Classification of Tumors Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Fourth ed. Lyon, France: IARC Press; 2008; 171-175.
  • 23
    Thomas DA, O'Brien S, Faderl S, et al Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010; 28: 3880-3889.
  • 24
    Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103: 4396-4407.
  • 25
    Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) (abstract). J Clin Oncol. 2010; 28: 15s. Abstract 6506.
  • 26
    Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010; 116: 2070-2077.
  • 27
    Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995; 9: 1783-1786.
  • 28
    Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 2005.
  • 29
    Luthra R, Sanchez-Vega B, Medeiros LJ. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol. 2004; 17: 96-103.
  • 30
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1965; 53: 457-481.
  • 31
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. J R Stat Soc. 1966; 50: 163-170.
  • 32
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187-220.
  • 33
    Boldt DH, Kopecky KJ, Head D, Gehly G, Radich JP, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia. 1994; 8: 2118-2126.
  • 34
    Putti MC, Rondelli R, Cocito MG, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood. 1998; 92: 795-801.
  • 35
    Nakase K, Kita K, Miwa H, et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia. 2007; 21: 326-332.
  • 36
    Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009; 113: 6330-6337.
  • 37
    Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Hematologica. 2010; 95: 324-328.
  • 38
    Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab in adult CD20 B-precursor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT (abstract). Hematologica. 2009; 94 ( suppl 2): 195. Abstract 481.
  • 39
    Santos FPS, O'Brien S, Thomas DA, et al. Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) (abstract). Blood. 2009; 114: 408. Abstract 984.
  • 40
    Yanada M, Takeuchi J, Sugiura I, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Hematologica. 2008; 93: 287-290.
  • 41
    Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Hematologica. 2010; 95: 87-95.
  • 42
    Pfeifer H, Wassmann B, Pavlova A, et al. Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) developing resistance to imatinib (abstract). Blood. 2005; 106: 46a. Abstract 147.
  • 43
    Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007; 110: 727-734.